Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
JACC Case Rep ; 22: 101996, 2023 Sep 20.
Article in English | MEDLINE | ID: mdl-37790765

ABSTRACT

We present the case of a 60-year-old man who presented with a post-myocardial infarction ventricular septal rupture caused by a delayed presentation of myocardial infarction. Despite revascularization, hemodynamic stability, and a 10-day delay until operative management to allow for tissue healing, the patient experienced a fatal recurrent postoperative ventricular septal rupture. (Level of Difficulty: Beginner.).

2.
Ann Thorac Surg ; 115(2): e41-e44, 2023 02.
Article in English | MEDLINE | ID: mdl-35305991

ABSTRACT

Management of rare ascending aortic complications after transcatheter aortic valve replacement (TAVR) remains a poorly defined area of knowledge. Furthermore, because most patients undergoing TAVR are at intermediate to high surgical risk, the treatment of such complications often requires endovascular approaches. Herein, we present a novel technique of endovascular ascending aorta stent graft delivery from the innominate artery for the treatment of a type A aortic dissection after self-expandable TAVR implantation, specifically addressing the landing of the aortic stent within the crown of the TAVR valve.


Subject(s)
Aortic Valve Stenosis , Dissection, Ascending Aorta , Endovascular Procedures , Transcatheter Aortic Valve Replacement , Humans , Transcatheter Aortic Valve Replacement/adverse effects , Transcatheter Aortic Valve Replacement/methods , Aorta/surgery , Stents , Endovascular Procedures/adverse effects , Treatment Outcome , Aortic Valve Stenosis/surgery , Aortic Valve Stenosis/etiology , Aortic Valve/surgery , Risk Factors
3.
JTCVS Tech ; 13: 9-10, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35711177
4.
Ann Transl Med ; 9(14): 1193, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34430634

ABSTRACT

Despite advances in detection and treatment, acute traumatic aortic injury (ATAI) is associated with high rates of morbidity and mortality. Both physical and hemodynamic forces have been postulated as mechanisms of aortic injury during a traumatic event. For patients who survive the initial injury, rapid detection is critical for diagnosis and procedural planning, which requires a thorough knowledge of both its clinical presentation and the available diagnostic imaging modalities. Radiography, computed tomography (CT), and magnetic resonance imaging (MRI) can each have a role in the diagnosis of ATAI. After stabilization of the patient, the management of ATAI is guided by the severity of injury. Appropriately selected patients with low grade injuries may be managed non-operatively. When treatment is required, there are both open surgical and endovascular options. In current practice, endovascular approaches with stent-graft placement are preferred due to their high clinical success and low rates of complications. Complications from endograft placement can include: endoleak, endograft collapse, infection, endograft failure, and endograft migration. Open surgical repair is now reserved for patients with unfavorable anatomy for endovascular therapies. This review provides a comprehensive overview of ATAI including its epidemiology and demographics, mechanisms of injury, clinical and radiographic diagnosis, treatment options, and post-therapeutic follow-up.

5.
Ann Thorac Surg ; 112(1): e5-e8, 2021 07.
Article in English | MEDLINE | ID: mdl-33422484

ABSTRACT

Endovascular stenting of the ascending aorta has been described for various aortic pathologies, including type A dissection in patients who are prohibitive risk for open surgery. Endovascular treatment of ascending aortic pathology poses unique anatomic and technical challenges related to aortic morphology. Herein, we present a novel technique of endovascular ascending stent graft delivery from a transfemoral approach for treatment of an acute type A dissection, utilizing a snare-guided deployment technique to facilitate favorable device deployment.


Subject(s)
Aorta/surgery , Aortic Aneurysm, Thoracic/surgery , Aortic Dissection/surgery , Blood Vessel Prosthesis Implantation/methods , Blood Vessel Prosthesis , Endovascular Procedures/methods , Acute Disease , Aged , Aortic Dissection/diagnosis , Aorta/diagnostic imaging , Aortic Aneurysm, Thoracic/diagnosis , Aortography/methods , Female , Humans , Microsurgery/methods , Prosthesis Design , Stents
6.
J Card Surg ; 35(10): 2825-2828, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32789877

ABSTRACT

Infectious complications following left ventricular assist device implantation can carry significant morbidity and mortality. The main tenet of treatment is source control which entails local wound care, intravenous antimicrobial therapy, surgical debridement, and at times, soft tissue flap coverage. The mode of therapy depends on the severity, etiology, and location of infection as well as the clinical status of the patient. We describe a case of a 46-year-old male who underwent left ventricular assist device placement complicated by pump thrombosis, recurrent infection, and hardware exposure who was successfully treated with a novel method of staged, soft tissue reconstruction.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Heart-Assist Devices/adverse effects , Prosthesis Design , Prosthesis Implantation/adverse effects , Prosthesis-Related Infections/therapy , Surgical Flaps , Connective Tissue/surgery , Debridement , Dosage Forms , Heart Ventricles , Humans , Male , Middle Aged , Prosthesis-Related Infections/etiology , Plastic Surgery Procedures/methods , Recurrence , Treatment Outcome
7.
Proc (Bayl Univ Med Cent) ; 33(1): 15-18, 2020 Jan.
Article in English | MEDLINE | ID: mdl-32063757

ABSTRACT

Anatomically, patients with refractory tracheal stenosis benefit from tracheal resection, depending on the medical comorbidities or challenging tracheal anatomy, which is often the reason for denial of this option in these patients. We evaluated 15 patients undergoing tracheal resection at our institution from May 2016 through December 2017. Eleven patients had a history of previous tracheostomy, six in place at the time of resection. One had idiopathic stenosis with no known comorbidities. Major comorbidities included chronic obstructive pulmonary disease, non-insulin-dependent diabetes mellitus, hypertension, and cardiovascular disease. One had a left ventricular assist device, and one was a lung transplant recipient. All had primary resection through the cervical approach with a median length of 3.5 cm. Fourteen patients were eventually decannulated. One patient had re-resection 1 year later for recurrent stenosis. Twelve were alive at a median follow-up of 15 months with patent airways. In conclusion, tracheal stenosis patients have significant comorbidities that increase the risks after resection. However, these patients should still be considered for surgery for an improved quality of life and eventual resolution of severe stenosis.

8.
J Thorac Dis ; 11(Suppl 6): S864-S870, 2019 Apr.
Article in English | MEDLINE | ID: mdl-31183166

ABSTRACT

BACKGROUND: Right heart failure (RHF) is a well-known consequence of left ventricular assist device (LVAD) placement, and has been linked to negative surgical outcomes. However, little is known regarding risk factors associated with RHF. This article delineates pre- and intra-operative risk factors for RHF following LVAD implantation and demonstrates the effect of RHF severity on key surgical outcomes. METHODS: We performed a retrospective analysis of consecutive LVAD patients treated at our center between 2008 and 2016. RHF was categorized using the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definition of none/mild, moderate, severe, and acute-severe. We constructed a predictive model using multivariable logistic regression and performed a competing risks analysis for survival stratified by RHF severity. RESULTS: Of 202 subjects, 52 (25.7%) developed moderate or worse RHF. Cardiopulmonary bypass (CPB) time and nadir hematocrit contributed jointly to the model of RHF severity (moderate or worse vs. none/mild; area under the curve =0.77). Postoperative length of stay (LOS) was shortest in the non/mild group and longest in the acute-severe group (median 13 vs. 29.5 days; P<0.001). Stage 2/3 acute kidney injury (range, 26-57%, P=0.002), respiratory failure (13-94%, P<0.001), stroke (0-32%, P=0.02), and 1-year mortality (19-64%, P=0.002) differed by severity. Those with acute-severe RHF had 5.4 [95% confidence interval (CI), 2.5-11.8] times the risk of 1-year mortality compared to those who did not have RHF. CONCLUSIONS: RHF remains a postoperative threat and is associated with worsened surgical outcomes. Ongoing research will reveal further opportunities to mitigate RHF post-LVAD.

9.
Cardiorenal Med ; 9(2): 100-107, 2019.
Article in English | MEDLINE | ID: mdl-30673661

ABSTRACT

BACKGROUND: Although acute kidney injury (AKI) is a common complication following cardiac surgery, less is known about the occurrence and consequences of moderate/severe AKI following left ventricular assist device (LVAD) implantation. METHODS: All patients who had an LVAD implanted at our center from 2008 to 2016 were reviewed to determine the incidence of, and risk factors for, moderate/severe (stage 2/3) AKI and to compare postoperative complications and mortality rates between those with and those without moderate/severe AKI. RESULTS: Of 246 patients, 68 (28%) developed moderate/severe AKI. A multivariable logistic regression comprising body mass index and prior sternotomy had fair predictive ability (area under the curve = 0.71). A 1-unit increase in body mass index increased the risk of moderate/severe AKI by 7% (odds ratio = 1.07; 95% confidence interval: 1.03-1.11); a prior sternotomy increased the risk more than 3-fold (odds ratio = 3.4; 95% confidence interval: 1.84-6.43). The group of patients with moderate/severe AKI had higher rates of respiratory failure and death than the group of patients with mild/no AKI. Patients with moderate/severe AKI were at 3.2 (95% confidence interval: 1.2-8.2) times the risk of 30-day mortality compared to those without. Even after adjusting for age and Interagency Registry for Mechanically Assisted Circulatory Support profile, those with moderate/severe AKI had 1.75 (95% confidence interval: 1.03-3.0) times the risk of 1-year mortality compared to those without. DISCUSSION: Risk-stratifying patients prior to LVAD placement in regard to AKI development may be a step toward improving surgical outcomes.


Subject(s)
Acute Kidney Injury/etiology , Cardiac Surgical Procedures/adverse effects , Heart Failure/surgery , Heart-Assist Devices/adverse effects , Acute Kidney Injury/diagnosis , Acute Kidney Injury/epidemiology , Aged , Female , Follow-Up Studies , Glomerular Filtration Rate/physiology , Heart Failure/physiopathology , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Survival Rate/trends , United States/epidemiology , Ventricular Function, Right/physiology
10.
Artif Organs ; 43(3): 234-241, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30357882

ABSTRACT

Left ventricular assist devices (LVADs) have improved clinical outcomes and quality of life for those with end-stage heart failure. However, the costs and risks associated with these devices necessitate appropriate patient selection. LVAD candidates are becoming increasingly more obese and there are conflicting reports regarding obesity's effect on outcomes. Hence, we sought to evaluate the impact of extreme obesity on clinical outcomes after LVAD placement. Consecutive LVAD implantation patients at our center from June 2008 to May 2016 were studied retrospectively. We compared patients with a body mass index (BMI) ≥40 kg/m2 (extremely obese) to those with BMI < 40 kg/m2 with respect to patient characteristics and surgical outcomes, including survival. 252 patients were included in this analysis, 30 (11.9%) of whom met the definition of extreme obesity. We found that patients with extreme obesity were significantly younger (47[33, 57] vs. 60[52, 67] years, P < 0.001) with fewer prior sternotomies (16.7% vs. 36.0%, P = 0.04). They had higher rates of pump thrombosis (30% vs. 9.0%, P = 0.003) and stage 2/3 acute kidney injury (46.7% vs. 27.0%, P = 0.003), but there were no differences in 30-day or 1-year survival, even after adjusting for age and clinical factors. Extreme obesity does not appear to place LVAD implantation patients at a higher risk for mortality compared to those who are not extremely obese; however, extreme obesity was associated with an increased risk of pump thrombosis, suggesting that these patients may require additional care to reduce the need for urgent device exchange.


Subject(s)
Heart Failure/surgery , Heart-Assist Devices , Obesity, Morbid/complications , Postoperative Complications/epidemiology , Prosthesis Implantation/adverse effects , Adult , Aged , Body Mass Index , Female , Heart Ventricles/surgery , Humans , Male , Middle Aged , Postoperative Complications/etiology , Prosthesis Implantation/methods , Quality of Life , Retrospective Studies , Treatment Outcome
11.
Curr Cardiol Rep ; 20(10): 82, 2018 08 09.
Article in English | MEDLINE | ID: mdl-30094642

ABSTRACT

PURPOSE OF REVIEW: To determine what influences patients and physicians to choose between transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) in intermediate-surgical-risk patients with severe, symptomatic aortic stenosis. RECENT FINDINGS: Advances in transcatheter valve technology, techniques, and trials demonstrating non-inferiority compared to surgical aortic valve replacement (SAVR) have led to expanded eligibility of transcatheter aortic valve replacement (TAVR) to both intermediate-risk patients in clinical practice and low-risk patients in pivotal trials. Since lower-risk individuals tend to be younger and good operative candidates, concerns of valve durability, procedure-related morbidity, and patient survivability require careful consideration. Results from the PARTNER II intermediate risk trials and SURTAVI trials have given us insight into the benefits and potential risks of both treatment modalities. In this article, we review the brief yet remarkable history of TAVR and discuss its role in the treatment of intermediate-surgical-risk patients.


Subject(s)
Aortic Valve Stenosis/surgery , Heart Valve Prosthesis Implantation/methods , Transcatheter Aortic Valve Replacement/methods , Humans , Randomized Controlled Trials as Topic , Risk Assessment , Risk Factors , Treatment Outcome
12.
Ann Thorac Cardiovasc Surg ; 24(4): 173-179, 2018 Aug 20.
Article in English | MEDLINE | ID: mdl-29877217

ABSTRACT

BACKGROUND: To investigate the efficacy of primary and rescue endoluminal vacuum (EVAC) therapy in the treatment of esophageal perforations and leaks. METHODS: We conducted a retrospective review of a prospectively gathered, Institutional Review Board (IRB) approved database of EVAC therapy patients at our center from July 2013 to September 2016. RESULTS: In all, 13 patients were treated for esophageal perforations or leaks. Etiologies included iatrogenic injury (n = 8), anastomotic leak (n = 2), Boerhaave syndrome (n = 1), and bronchoesophageal fistula (n = 2). In total, 10 patients underwent primary treatment and three were treated with rescue therapy. Mean Perforation Severity Scores (PSSs) in the primary and rescue treatment groups were 7 and 10, respectively. Average defect size was 2.4 (range: 0.5-6) cm. The rescue group had a shorter mean time to defect closure (25 vs. 33 days). In all, 12 of 13 defects healed. One death occurred following the implementation of comfort care. One therapy-specific complication occurred. Hospital length of stay (LOS) was longer in the rescue group (72 vs. 53 days); however, the intensive care unit (ICU) duration was similar between groups. Totally, 10 patients (83%) resumed an oral diet after successful defect closure. CONCLUSION: Utilized as either a primary or rescue therapy, EVAC therapy appears to be beneficial in the management of esophageal perforations or leaks.


Subject(s)
Anastomotic Leak/therapy , Bronchial Fistula/therapy , Esophageal Fistula/therapy , Esophageal Perforation/therapy , Esophagoscopy , Iatrogenic Disease , Mediastinal Diseases/therapy , Negative-Pressure Wound Therapy , Aged , Aged, 80 and over , Anastomotic Leak/etiology , Anastomotic Leak/mortality , Bronchial Fistula/etiology , Bronchial Fistula/mortality , Databases, Factual , Esophageal Fistula/etiology , Esophageal Fistula/mortality , Esophageal Perforation/etiology , Esophageal Perforation/mortality , Esophagoscopy/adverse effects , Esophagoscopy/instrumentation , Esophagoscopy/mortality , Female , Humans , Length of Stay , Male , Mediastinal Diseases/etiology , Mediastinal Diseases/mortality , Middle Aged , Negative-Pressure Wound Therapy/adverse effects , Negative-Pressure Wound Therapy/instrumentation , Negative-Pressure Wound Therapy/mortality , Retrospective Studies , Risk Factors , Surgical Sponges , Time Factors , Treatment Outcome , Wound Healing
13.
Proc (Bayl Univ Med Cent) ; 31(2): 192-193, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29706816

ABSTRACT

Foreign body perforations of the esophagus are infrequent events yet have the potential to cause significant morbidity and mortality. The clinical consequences of esophageal perforation by a foreign body are dependent upon the severity of infectious sequelae and damage to surrounding structures by the foreign object itself, as detailed in previous published reports. We describe the thoracoscopic management of a mediastinal abscess caused by a foreign body perforation in a patient with an intact esophagus.

14.
Proc (Bayl Univ Med Cent) ; 31(2): 210-212, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29706823

ABSTRACT

Carcinosarcoma is a rare subtype of pancreatic neoplasm including both carcinomatous and sarcomatous components. Fewer than 30 cases have been reported to the Surveillance, Epidemiology, and End Results Program database. Given such rarity, definitive treatment guidelines are not well defined. We report a case of pancreatic carcinosarcoma diagnosed in our institution, review tumor clinicopathological characteristics, and describe our medical and surgical management strategy.

15.
J Am Heart Assoc ; 7(11)2018 05 17.
Article in English | MEDLINE | ID: mdl-29773577

ABSTRACT

BACKGROUND: Vasoplegia is associated with adverse outcomes following cardiac surgery; however, its impact following left ventricular assist device implantation is largely unexplored. METHODS AND RESULTS: In 252 consecutive patients receiving a left ventricular assist device, vasoplegia was defined as the occurrence of normal cardiac function and index but with the need for intravenous vasopressors within 48 hours following surgery for >24 hours to maintain a mean arterial pressure >70 mm Hg. We further categorized vasoplegia as none; mild, requiring 1 vasopressor (vasopressin, norepinephrine, or high-dose epinephrine [>5 µg/min]); or moderate to severe, requiring ≥2 vasopressors. Predictors of vasoplegia severity were determined using a cumulative logit (ordinal logistic regression) model, and 1-year mortality was evaluated using competing-risks survival analysis. In total, 67 (26.6%) patients developed mild vasoplegia and 57 (22.6%) developed moderate to severe vasoplegia. The multivariable model for vasoplegia severity utilized preoperative Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile, central venous pressure, systolic blood pressure, and intraoperative cardiopulmonary bypass time, which yielded an area under the curve of 0.76. Although no significant differences were noted in stroke or pump thrombosis rates (P=0.87 and P=0.66, respectively), respiratory failure and major bleeding increased with vasoplegia severity (P<0.01). Those with moderate to severe vasoplegia had a significantly higher risk of mortality than those without vasoplegia (adjusted hazard ratio: 2.12; 95% confidence interval, 1.08-4.18; P=0.03). CONCLUSIONS: Vasoplegia is predictive of unfavorable outcomes, including mortality. Risk factors for future research include preoperative INTERMACS profile, central venous pressure, systolic blood pressure, and intraoperative cardiopulmonary bypass time.


Subject(s)
Arterial Pressure , Heart Failure/therapy , Heart-Assist Devices , Prosthesis Implantation/adverse effects , Prosthesis Implantation/instrumentation , Vasoplegia/etiology , Ventricular Function, Left , Aged , Arterial Pressure/drug effects , Cardiopulmonary Bypass , Central Venous Pressure , Female , Heart Failure/mortality , Heart Failure/physiopathology , Humans , Male , Middle Aged , Prosthesis Design , Prosthesis Implantation/mortality , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Time Factors , Treatment Outcome , Vasoconstrictor Agents/therapeutic use , Vasoplegia/drug therapy , Vasoplegia/mortality , Vasoplegia/physiopathology
16.
Interact Cardiovasc Thorac Surg ; 27(3): 343-349, 2018 09 01.
Article in English | MEDLINE | ID: mdl-29584854

ABSTRACT

OBJECTIVES: Prior sternotomy is associated with increased morbidity and mortality following heart transplantation. However, its effect on primary graft dysfunction (PGD), a major contributor to early mortality, is unknown. Herein, this effect is studied using the International Society for Heart and Lung Transplantation consensus definition for PGD. METHODS: Medical records of consecutive adult cardiac transplants between 2012 and 2016 were reviewed. Baseline characteristics, postoperative findings and 1-year survival were compared between patients with and without prior sternotomy. RESULTS: Among 255 total patients included, 139 (55%) had undergone prior sternotomy; these recipients were older, more often male, had higher body mass index, higher frequencies of united network for organ sharing (UNOS) 1A status and ischaemic cardiomyopathy and experienced longer waitlist times when compared with those without prior sternotomy (all P < 0.018). Postoperatively, the prior sternotomy group exhibited higher rates of mild to severe PGD (32% vs 18%; P = 0.015) and higher short-term mortality (P = 0.017) and 1-year mortality (P = 0.047). They required more blood transfusions, had more postoperative pneumonia, wound infection and longer hospital stays. A stepwise multivariable regression model identified prior sternotomy as a predictor of PGD (odds ratio 2.7). Multiple prior sternotomies was associated with even more UNOS 1A status, ischaemic cardiomyopathy and pneumonia. However, logistic modelling did not show a difference in the rate of PGD between those with 1 or ≥2 prior sternotomies. CONCLUSIONS: Our data suggest that prior sternotomy is a risk factor for PGD. Consistent with previous reports, prior sternotomy is associated with increased morbidity, blood product utilization and 1-year mortality following cardiac transplantation.


Subject(s)
Heart Failure/surgery , Heart Transplantation/adverse effects , Primary Graft Dysfunction/etiology , Reoperation/adverse effects , Sternotomy/adverse effects , Aged , Female , Humans , Logistic Models , Male , Middle Aged , Odds Ratio , Retrospective Studies , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...